Sprangers Ben
Department of Microbiology and Immunology, Laboratory of Experimental Transplantation, KU Leuven, Leuven, Belgium.
Department of Nephrology, University Hospitals Leuven, Leuven, Belgium.
Clin Kidney J. 2019 Feb;12(1):78-80. doi: 10.1093/ckj/sfy114. Epub 2018 Dec 1.
Checkpoint inhibitors are increasingly used to treat different types of malignancy and have been associated with renal toxicities. In this issue, Izzedine report on the incidence of pembrolizumab-associated renal toxicity in a French single-centre nephrology referral centre. They report an estimated incidence of pembrolizumab-related renal toxicities of 1.77% and most notably the most common histologic lesion was acute tubular injury (not acute tubulo-interstitial nephritis). This study further highlights the importance of performing a thorough nephrological workup including kidney biopsy in patients experiencing renal toxicities while receiving pembrolizumab treatment.
检查点抑制剂越来越多地用于治疗不同类型的恶性肿瘤，并且与肾毒性有关。在本期中，伊泽丁报告了法国一家单中心肾脏病转诊中心帕博利珠单抗相关肾毒性的发生率。他们报告帕博利珠单抗相关肾毒性的估计发生率为1.77%，最值得注意的是，最常见的组织学病变是急性肾小管损伤（而非急性肾小管间质性肾炎）。这项研究进一步强调了在接受帕博利珠单抗治疗的患者出现肾毒性时，进行包括肾活检在内的全面肾脏病检查的重要性。
